


MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
Effective Date: 1/1/2023	Medical Policy Number: 23
 1/1/2023	Medical Policy Committee Approved Date: 7/17; 12/17; 6/18; 8/18; 10/18; 12/18; 1/19; 3/19; 9/19; 11/19; 12/19; 4/2020; 6/2020; 7/2020; 8/2020; 9/2020; 10/2020; 12/2020; 2/2021; 03/2021; 6/2021; 9/2021; 11/2021; 12/2021; 3/2022; 6/2022; 6/2022; 8/2022; 9/2022; 10/2022; 11/2022
Medical Officer	Date

See Policy CPT/HCPCS CODE section below for any prior authorization requirements

SCOPE:

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayn Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

APPLIES TO:

All lines of business except Medicare (unless otherwise directed by a Medicare medical policy. Note that investigational services are considered “not medically necessary” for Medicare members.)

BENEFIT APPLICATION

Medicaid Members

Oregon: Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

POLICY CRITERIA

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding each of the medical technologies listed in the CPT/HCPCS CODE section below. The evidence was determined to be insufficient to support the clinical utility, diagnostic efficacy, and/or safety of these technologies. Additional high-quality studies are needed to establish the long-term efficacy, durability, and safety of these technologies for any condition; therefore, all the following medical services listed in the CPT/HCPCS CODE section below are considered **investigational and are not covered**.

Link to [Policy Summary](#)

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

CPT/HCPCS CODES

All Lines of Business Except Medicare			
Not Covered			
CPT Temporary (T) Codes			
Code	Description	Manufacturer & Device Name (if applicable)	
0100T	Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy	-	
0190T	Placement of intraocular radiation source applicator (List separately in addition to primary procedure)	NeoVista Epi-Rad90™ Ophthalmic System	
0213T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; single level	-	
0214T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; second level (List separately in addition to code for primary procedure)		
0215T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure)		
0216T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; single level		
0217T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; second level (List separately in addition to code for primary procedure)		
0218T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure)		
0219T	Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; cervical		TruFUSE® by miniSURG™ Corp.

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

0220T	Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; thoracic	
0221T	Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; lumbar	
0222T	Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; each additional vertebral segment (List separately in addition to code for primary procedure)	
0329T	Monitoring of intraocular pressure for 24 hours or longer, unilateral or bilateral, with interpretation and report	SENSIMED Triggerfish® by Sensimed AG
0335T	Extra-osseous subtalar joint implant for talotarsal stabilization	–
0337T	Endothelial function assessment, using peripheral vascular response to reactive hyperemia, non-invasive (eg, brachial artery ultrasound, peripheral artery tonometry), unilateral or bilateral	EndoPAT™ 2000 by Itamar Medical Ltd.
0338T	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral	Symlicity™ Renal Denervation (RDN) System by Medtronic EnligHTN™ multi- electrode renal denervation system by St. Jude Medical™
0339T	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral	One-Shot™ Renal Denervation System by Covidien Vessix™ Renal Denervation System by Boston Scientific™ CARTO® Thermocool Smarttouch® Catheter by Biosense Webster®
0351T	Optical coherence tomography of breast or axillary lymph node, excised tissue, each specimen; real-time intraoperative	RS-3000 Advance by NIDEK©

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

0352T	Optical coherence tomography of breast or axillary lymph node, excised tissue, each specimen; interpretation and report, real-time or referred	
0353T	Optical coherence tomography of breast, surgical cavity; real-time intraoperative	
0354T	Optical coherence tomography of breast, surgical cavity; interpretation and report, real-time or referred	
0356T	TERMED 12/31/2021 Insertion of drug-eluting implant (including punctal dilation and implant removal when performed) into lacrimal canaliculus, each	OTX-TP (travoprost insert) by Ocular Therapeutix™, Inc.
0378T	Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional	ForeseeHome® age-related macular degeneration (AMD) Monitoring Program by Notal Vision™, Ltd.
0379T	Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; technical support and patient instructions, surveillance, analysis, and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional	
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed	-
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed	
0397T	Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure)	MagniView EC-3890Zi Video Colonoscope BY Pentax Medical
0398T	Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation lesion, intracranial for movement disorder including stereotactic navigation and frame placement when performed	-
0404T	Transcervical uterine fibroid(s) ablation with ultrasound guidance, radiofrequency	-
0406T	Nasal endoscopy, surgical, ethmoid sinus, placement of drug eluting implant	PROPEL® Sinus Implant (Intersect® ENT)
0407T	Nasal endoscopy, surgical, ethmoid sinus, placement of drug eluting implant; with biopsy, polypectomy or debridement	
0408T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when	Cardiac Contractility Modulation (CCM)

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

	performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrodes	System by Impulse Dynamics	
0409T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only		
0410T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only		
0411T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only		
0412T	Removal of permanent cardiac contractility modulation system; pulse generator only		
0413T	Removal of permanent cardiac contractility modulation system; transvenous electrode (atrial or ventricular)		
0414T	Removal and replacement of permanent cardiac contractility modulation system pulse generator only		
0415T	Repositioning of previously implanted cardiac contractility modulation transvenous electrode (atrial or ventricular lead)		
0416T	Relocation of skin pocket for implanted cardiac contractility modulation pulse generator		
0417T	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system		
0418T	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable cardiac contractility modulation system		
0422T	Tactile breast imaging by computer-aided tactile sensors, unilateral or bilateral		Breastview Visual Mapping System by Medical Tactile, Inc. iBreast Exam™ (iBE) by UE LifeSciences Inc.
0424T	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement		

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

	of right or left stimulation lead, sensing lead, implantable pulse generator)	Remedē® System by Respicardia®
0425T	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; sensing lead only	
0426T	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only	
0427T	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; pulse generator only	
0428T	Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only	
0429T	Removal of neurostimulator system for treatment of central sleep apnea; sensing lead only	
0430T	Removal of neurostimulator system for treatment of central sleep apnea; stimulation lead only	
0431T	Removal and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only	
0432T	Repositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead only	
0433T	Repositioning of neurostimulator system for treatment of central sleep apnea; sensing lead only	
0434T	Interrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea	
0435T	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session	
0436T	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study	
0443T	Real time spectral analysis of prostate tissue by fluorescence spectroscopy	ClariCore™ Biopsy System by Precision Biopsy™
0444T	Initial placement of a drug-eluting ocular insert under one or more eyelids, including fitting, training, and insertion, unilateral or bilateral	Dextenza™ by Ocular Therapeutix™, Inc.
0445T	Subsequent placement of a drug-eluting ocular insert under one or more eyelids, including re-training, and removal of existing insert, unilateral or bilateral	
0449T	Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; initial device	AqueSys XEN® Gel Stent by Allergan
0450T	Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; each additional device (List separately in addition to code for primary procedure)	

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

0469T	Retinal polarization scan, ocular screening with on-site automated results, bilateral	-
0470T	TERMED 12/31/2022 Optical coherence tomography (OCT) for microstructural and morphological imaging of skin, image acquisition, interpretation, and report; first lesion	
0471T	TERMED 12/31/2022 Optical coherence tomography (OCT) for microstructural and morphological imaging of skin, image acquisition, interpretation, and report; each additional lesion (List separately in addition to code for primary procedure)	-
0472T	Device evaluation, interrogation, and initial programming of intra-ocular retinal electrode array (eg, retinal prosthesis), in person, with iterative adjustment of the implantable device to test functionality, select optimal permanent programmed values with analysis, including visual training, with review and report by a qualified health care professional	-
0473T	Device evaluation and interrogation of intra-ocular retinal electrode array (eg, retinal prosthesis), in person, including reprogramming and visual training, when performed, with review and report by a qualified health care professional	
0481T	Injection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed	-
0485T	Optical coherence tomography (OCT) of middle ear, with interpretation and report; unilateral	-
0486T	Optical coherence tomography (OCT) of middle ear, with interpretation and report; bilateral	-
0487T	TERMED 12/31/2022 Biomechanical mapping, transvaginal, with report	-
0489T	Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; adipose tissue harvesting, isolation and preparation of harvested cells including incubation with cell dissociation enzymes, removal of non-viable cells and debris, determination of concentration and dilution of regenerative cells	-
0490T	Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; multiple injections in one or both hands	
0491T	TERMED 12/31/2022 Ablative laser treatment, non-contact, full field and fractional ablation, open wound, per day, total treatment surface area; first 20 sq cm or less	-
0492T	TERMED 12/31/2022	-

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
----------------	---

	Ablative laser treatment, non-contact, full field and fractional ablation, open wound, per day, total treatment surface area; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)	
0493T	TERMED 12/31/2022 Contact near-infrared spectroscopy studies of lower extremity wounds (eg, for oxyhemoglobin measurement)	–
0506T	Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report	MacuScope™ by Medelsis
0507T	Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report	LipiScan™ Dynamic Meibomian Imager™ (DMI) by TearScience®
0508T	Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia	Bindex® by Bone Index Finland Ltd.
0510T	Removal of sinus tarsi implant	–
0511T	Removal and reinsertion of sinus tarsi implant	–
0512T	Extracorporeal shock wave for integumentary wound healing, including topical application and dressing care; initial wound	–
0515T	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])	–
0516T	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only	
0517T	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only	
0518T	Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing	
0519T	Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter)	
0520T	Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode	
0521T	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per	

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

	patient encounter, wireless cardiac stimulator for left ventricular pacing		
0522T	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing		
0525T	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)	AngelMed® Guardian System by Angel Medical Systems	
0526T	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only		
0527T	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only		
0528T	Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report		
0529T	Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report		
0530T	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)		
0531T	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only		
0532T	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only		
0533T	Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report		
0534T	Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor		-
0535T	Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration		

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

0536T	Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report	
0544T	Transcatheter mitral valve annulus reconstruction, with implantation of adjustable annulus reconstruction device, percutaneous approach including transeptal puncture	—
0545T	Transcatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus reconstruction device, percutaneous approach	—
0546T	Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report	—
0547T	Bone-material quality testing by microindentation(s) of the tibia(s), with results reported as a score	—
0553T	Percutaneous transcatheter placement of iliac arteriovenous anastomosis implant, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention	—
0554T	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report	—
0555T	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data	—
0556T	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; assessment of bone strength and fracture risk and bone mineral density	—
0557T	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; interpretation and report	—
0558T	Computed tomography scan taken for the purpose of biomechanical computed tomography analysis	
0559T	Anatomic model 3D-printed from image data set(s); first individually prepared and processed component of an anatomic structure	—
0560T	Anatomic model 3D-printed from image data set(s); each additional individually prepared and processed component of an anatomic structure (List separately in addition to code for primary procedure)	—

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

0561T	Anatomic guide 3D-printed and designed from image data set(s); first anatomic guide	—
0562T	Anatomic guide 3D-printed and designed from image data set(s); each additional anatomic guide (List separately in addition to code for primary procedure)	—
0567T	Permanent fallopian tube occlusion with degradable biopolymer implant, transcervical approach, including transvaginal ultrasound	—
0568T	Introduction of mixture of saline and air for sonosalpingography to confirm occlusion of fallopian tubes, transcervical approach, including transvaginal ultrasound and pelvic ultrasound	—
0569T	Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis	Abbot TriClip Transcatheter Tricuspid Valve Repair System
0570T	Transcatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure)	
0571T	Insertion or replacement of implantable cardioverter-defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed	—
0572T	Insertion of substernal implantable defibrillator electrode	—
0573T	Removal of substernal implantable defibrillator electrode	—
0574T	Repositioning of previously implanted substernal implantable defibrillator-pacing electrode	—
0575T	Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional	—
0576T	Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter	—
0577T	Electrophysiological evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and	—

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
----------------	---

	programming or reprogramming of sensing or therapeutic parameters)	
0578T	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional	—
0579T	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results	—
0580T	Removal of substernal implantable defibrillator pulse generator only	—
0581T	Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral	—
0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance	Rezum®
0583T	Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia	—
0594T	Osteotomy, humerus, with insertion of an externally controlled intramedullary lengthening device, including intraoperative imaging, initial and subsequent alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device	FITBONE® System PRECICE UNYTE® Nail
0598T	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (eg, lower extremity)	MolecuLight i:X™
0599T	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; each additional anatomic site (eg, upper extremity) (List separately in addition to code for primary procedure)	MolecuLight i:X™
0602T	Glomerular filtration rate (GFR) measurement(s), transdermal, including sensor placement and administration of a single dose of fluorescent pyrazine agent	MediBeacon's Transdermal GFR Measurement System (TGFR) and patented pharmaceutical Lumitrace™
0603T	Glomerular filtration rate (GFR) monitoring, transdermal, including sensor placement and administration of more than one dose of fluorescent pyrazine agent, each 24 hours	MediBeacon's Transdermal GFR Measurement System (TGFR) and

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

		patented pharmaceutical Lumitrace™
0604T	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; initial device provision, set-up and patient education on use of equipment	Home OCT (Notal Vision)
0605T	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; remote surveillance center technical support, data analyses and reports, with a minimum of 8 daily recordings, each 30 days	Home OCT (Notal Vision)
0606T	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; review, interpretation and report by the prescribing physician or other qualified health care professional of remote surveillance center data analyses, each 30 days	Home OCT (Notal Vision)
0607T	Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; set-up and patient education on use of equipment	
0608T	Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; analysis of data received and transmission of reports to the physician or other qualified health care professional	
0609T	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); acquisition of single voxel data, per disc, on biomarkers (ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs	NOCISCAN™ Suite (Nocimed)
0610T	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis	NOCISCAN™ Suite (Nocimed)
0611T	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); postprocessing	NOCISCAN™ Suite (Nocimed)

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

	for algorithmic analysis of biomarker data for determination of relative chemical differences between discs	
0612T	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); interpretation and report	NOCISCAN™ Suite (Nocimed)
0613T	Percutaneous transcatheter implantation of interatrial septal shunt device, including right and left heart catheterization, intracardiac echocardiography, and imaging guidance by the proceduralist, when performed	InterAtrial Shunt Device (IASD), Corvia Medical
0614T	Removal and replacement of substernal implantable defibrillator pulse generator	Extravascular Implantable Cardioverter Defibrillator (EV ICD) system, Medtronic
0615T	Eye-movement analysis without spatial calibration, with interpretation and report	EyeBOX exam, Oculogica
0616T	Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; without removal of crystalline lens or intraocular lens, without insertion of intraocular lens	CustomFlex Artificial Iris, Human Optics
0617T	Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with removal of crystalline lens and insertion of intraocular lens	CustomFlex Artificial Iris, Human Optics
0618T	Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with secondary intraocular lens placement or intraocular lens exchange	CustomFlex Artificial Iris, Human Optics
0621T	Trabeculostomy ab interno by laser	
0622T	Trabeculostomy ab interno by laser; with use of ophthalmic endoscope	
0623T	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report	
0624T	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission	
0625T	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography;	

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

	computerized analysis of data from coronary computed tomographic angiography	
0626T	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report	
0631T	Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity	
0632T	Percutaneous transcatheter ultrasound ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance	
0639T	Wireless skin sensor thermal anisotropy measurement(s) and assessment of flow in cerebrospinal fluid shunt, including ultrasound guidance, when performed	
0640T	Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO ₂]); image acquisition, interpretation and report, each flap or wound	
0641T	Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO ₂]); image acquisition only, each flap or wound	
0642T	Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO ₂]); interpretation and report only, each flap or wound	
0643T	Transcatheter left ventricular restoration device implantation including right and left heart catheterization and left ventriculography when performed, arterial approach	Revivent TC System - BioVentrix
0644T	Transcatheter removal or debulking of intracardiac mass (eg, vegetations, thrombus) via suction (eg, vacuum, aspiration) device, percutaneous approach, with intraoperative reinfusion of aspirated blood, including imaging guidance, when performed	AngioVac System
0645T	Transcatheter implantation of coronary sinus reduction device including vascular access and closure, right heart catheterization, venous angiography, coronary sinus angiography, imaging guidance, and supervision and interpretation, when performed	Neovasc Reducer
0646T	Transcatheter tricuspid valve implantation/replacement (TTVI) with prosthetic valve, percutaneous approach, including right heart	Intrepid Transcatheter Mitral

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

	catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed	Valve Replacement System (Medtronic)
0647T	Insertion of gastrostomy tube, percutaneous, with magnetic gastropexy, under ultrasound guidance, image documentation and report	Puma-G System (Ultrasound Gastronomy)
0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging	Visualase Laser Ablation, Medtronic
0656T	Vertebral body tethering, anterior; up to 7 vertebral segments	
0657T	Vertebral body tethering, anterior; 8 or more vertebral segments	
0658T	Electrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk score	Nevisense, SciBase
0659T	Transcatheter intracoronary infusion of supersaturated oxygen in conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation	TherOx Downstream® System, TherOx Inc
0660T	Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach	
0661T	Removal and reimplantation of anterior segment intraocular nonbiodegradable drug-eluting implant	
0673T	Ablation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance	
0674T	Laparoscopic insertion of new or replacement of permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including an implantable pulse generator and diaphragmatic lead(s)	
0675T	Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first lead	
0676T	Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional lead (List separately in addition to code for primary procedure)	
0677T	Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first repositioned lead	
0678T	Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for	

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

	augmentation of cardiac function, including connection to an existing pulse generator; each additional repositioned lead (List separately in addition to code for primary procedure)	
0679T	Laparoscopic removal of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	
0680T	Insertion or replacement of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing lead(s)	
0681T	Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads	
0682T	Removal of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	
0683T	Programming device evaluation (in-person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	
0684T	Peri-procedural device evaluation (in-person) and programming of device system parameters before or after a surgery, procedure, or test with analysis, review, and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	
0685T	Interrogation device evaluation (in-person) with analysis, review and report by a physician or other qualified health care professional, including connection, recording and disconnection per patient encounter, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	
0687T	Treatment of amblyopia using an online digital program; device supply, educational set-up, and initial session	
0688T	Treatment of amblyopia using an online digital program; assessment of patient performance and program data by physician or other qualified health care professional, with report, per calendar month	

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

0689T	Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained without diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure)	
0690T	Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained with diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure)	
0691T	Automated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report	
0693T	Comprehensive full body computer-based markerless 3D kinematic and kinetic motion analysis and report	
0695T	Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of implant or replacement	
0696T	Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of follow-up interrogation or programming device evaluation	
0697T	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session; multiple organs	
0698T	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure); multiple organs (List separately in addition to code for primary procedure)	
0700T	Molecular fluorescent imaging of suspicious nevus; first lesion	
0701T	Molecular fluorescent imaging of suspicious nevus; each additional lesion (List separately in addition to code for primary procedure)	
0704T	Remote treatment of amblyopia using an eye tracking device; device supply with initial set-up and patient education on use of equipment	

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

0705T	Remote treatment of amblyopia using an eye tracking device; surveillance center technical support including data transmission with analysis, with a minimum of 18 training hours, each 30 days	
0706T	Remote treatment of amblyopia using an eye tracking device; interpretation and report by physician or other qualified health care professional, per calendar month	
0707T	Injection(s), bone-substitute material (eg, calcium phosphate) into subchondral bone defect (ie, bone marrow lesion, bone bruise, stress injury, microtrabecular fracture), including imaging guidance and arthroscopic assistance for joint visualization	
0715T	Percutaneous transluminal coronary lithotripsy (List separately in addition to code for primary procedure)	
0716T	Cardiac acoustic waveform recording with automated analysis and generation of coronary artery disease risk score	
0720T	Percutaneous electrical nerve field stimulation, cranial nerves, without implantation	
0725T	Vestibular device implantation, unilateral	
0726T	Removal of implanted vestibular device, unilateral	
0727T	Removal and replacement of implanted vestibular device, unilateral	
0728T	Diagnostic analysis of vestibular implant, unilateral; with initial programming	
0729T	Diagnostic analysis of vestibular implant, unilateral; with subsequent programming	
0730T	Trabeculotomy by laser, including optical coherence tomography (OCT) guidance	ExTra ELT by ELT Sight
0731T	Augmentative AI-based facial phenotype analysis with report	
0732T	Immunotherapy administration with electroporation, intramuscular	
0733T	Remote real-time, motion capture-based neurorehabilitative therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days	
0734T	Remote real-time, motion capture-based neurorehabilitative therapy ordered by a physician or other qualified health care professional; treatment management services by a physician or other qualified health care professional, per calendar month	
0735T	Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure)	
0736T	Colonic lavage, 35 or more liters of water, gravity-fed, with induced defecation, including insertion of rectal catheter	

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

0737T	Xenograft implantation into the articular surface	
0738T	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination	
0739T	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation	
0743T	Bone strength and fracture risk using finite element analysis of functional data and bone mineral density (BMD), with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and BMD and classification of any vertebral fractures, with overall fracture-risk assessment, interpretation and report	
0744T	Insertion of bioprosthetic valve, open, femoral vein, including duplex ultrasound imaging guidance, when performed, including autogenous or nonautogenous patch graft (eg, polyester, ePTFE, bovine pericardium), when performed	
0748T	Injections of stem cell product into perianal perifistular soft tissue, including fistula preparation (eg, removal of setons, fistula curettage, closure of internal openings)	
0764T	Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently performed electrocardiogram (List separately in addition to code for primary procedure)	
0765T	Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously performed electrocardiogram	
0770T	Virtual reality technology to assist therapy (List separately in addition to code for primary procedure)	
0771T	Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older	

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

0772T	Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; each additional 15 minutes intraservice time (List separately in addition to code for primary service)	
0773T	Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; initial 15 minutes of intraservice time, patient age 5 years or older	
0774T	Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service)	
0777T	Real-time pressure-sensing epidural guidance system (List separately in addition to code for primary procedure)	
0778T	Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function	
0779T	Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report	
0781T	Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; bilateral mainstem bronchi	
0782T	Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; unilateral mainstem bronchus	

CPT Codes

Code	Description	Manufacturer & Device Name (if applicable)
57465	Computer-aided mapping of cervix uteri during colposcopy, including optical dynamic spectral imaging and algorithmic	DYSIS Medical digital colposcope

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

	quantification of the acetowhitening effect (List separately in addition to code for primary procedure)	
58674	Laparoscopy, surgical, ablation of uterine fibroid(s) including intraoperative ultrasound guidance and monitoring, radiofrequency	
62263	Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 2 or more days	
62264	Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 1 day	
64910	Nerve repair; with synthetic conduit or vein allograft (eg, nerve tube), each nerve	—
68841	Insertion of drug-eluting implant, including punctal dilation when performed, into lacrimal canaliculus, each	
77089	Trabecular bone score (TBS), structural condition of the bone microarchitecture; using dual X-ray absorptiometry (DXA) or other imaging data on gray-scale variogram, calculation, with interpretation and report on fracture-risk	
77090	Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical preparation and transmission of data for analysis to be performed elsewhere	
77091	Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical calculation only	
77092	Trabecular bone score (TBS), structural condition of the bone microarchitecture; interpretation and report on fracture-risk only by other qualified health care professional	
77422	High energy neutron radiation treatment delivery; single treatment area using a single port or parallel-opposed ports with no blocks or simple blocking	—
77423	High energy neutron radiation treatment delivery; 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s)	
81506	Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, HbA1c, insulin, hs-CRP, adiponectin, ferritin, interleukin 2-receptor alpha), utilizing serum or plasma, algorithm reporting a risk score	<p>Boston Heart Prediabetes Assessment®</p> <p>PreDx® Diabetes Risk Score (DRS) by</p>

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

		Tethys Bioscience, Inc
83951	Oncoprotein; des-gamma-carboxy-prothrombin (DCP)	—
93590	Percutaneous transcatheter closure of paravalvular leak; initial occlusion device, mitral valve	
93591	Percutaneous transcatheter closure of paravalvular leak; initial occlusion device, aortic valve	
95919	Quantitative pupillometry with physician or other qualified health care professional interpretation and report, unilateral or bilateral	
96931	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition and interpretation and report, first lesion	VivaScope® 1500 by Caliber Imaging & Diagnostics, Inc.
96932	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition only, first lesion	
96933	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; interpretation and report only, first lesion	
96934	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition and interpretation and report, each additional lesion (List separately in addition to code for primary procedure)	
96935	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition only, each additional lesion (List separately in addition to code for primary procedure)	
96936	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; interpretation and report only, each additional lesion (List separately in addition to code for primary procedure)	
97610	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day	

HCPCS Codes		
Code	Description	Manufacturer & Device Name (if applicable)
A6000	Non-contact wound warming wound cover for use with the non-contact wound warming device and warming card	
C1761	Catheter, transluminal intravascular lithotripsy, coronary	Shockwave Coronary Rx Lithoplasty System
C1824	Generator, cardiac contractility modulation (implantable)	Cardiac Contractility Modulation for Chronic Heart Failure

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

		(i.e., Optimizer by Impulse Dynamics)
C1833	Monitor, cardiac, including intracardiac lead and all system components (implantable)	
C9048	Dexamethasone, lacrimal ophthalmic insert, 0.1 mg	Dextenza by Ocular Therapeutix, Inc.
C9122	Mometasone furoate sinus implant, 10 micrograms (sinuva)	Sinuva®
C9352	Microporous collagen implantable tube (neuragen nerve guide), per centimeter length	—
C9353	Microporous collagen implantable slit tube (neurawrap nerve protector), per centimeter length	—
C9355	Collagen nerve cuff (neuromatrix), per 0.5 centimeter length	—
C9361	Collagen matrix nerve wrap (neuromend collagen nerve wrap), per 0.5 centimeter length	—
C9759	Transcatheter intraoperative blood vessel microinfusion(s) (e.g., intraluminal, vascular wall and/or perivascular) therapy, any vessel, including radiological supervision and interpretation, when performed	Bullfrog Micro-infusion device by Mercator Medsystems
C9781	Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed	InSpace Subacromial Spacer by Stryker
C9764	Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed	Shockwave Medical Peripheral IVL System by Shockwave Medical Inc
C9765	Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed	Shockwave Medical Peripheral IVL System by Shockwave Medical Inc
C9766	Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed	Shockwave Medical Peripheral IVL System by Shockwave Medical Inc
C9767	Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed	Shockwave Medical Peripheral IVL System by Shockwave Medical Inc

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

C9768	Endoscopic ultrasound-guided direct measurement of hepatic portosystemic pressure gradient by any method (list separately in addition to code for primary procedure)	Echotip by Cook Medical
C9771	Nasal/sinus endoscopy, cryoablation nasal tissue(s) and/or nerve(s), unilateral or bilateral	Clarifix by Arrinex Inc
C9772	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies), with intravascular lithotripsy, includes angioplasty within the same vessel (s), when performed	Shockwave Medical Peripheral IVL System by Shockwave Medical Inc
C9773	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed	Shockwave Medical Peripheral IVL System by Shockwave Medical Inc
C9774	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel (s), when performed	Shockwave Medical Peripheral IVL System by Shockwave Medical Inc
C9775	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel (s), when performed	Shockwave Medical Peripheral IVL System by Shockwave Medical Inc
C9780	Insertion of central venous catheter through central venous occlusion via inferior and superior approaches (e.g., inside-out technique), including imaging guidance	Surfacer® Inside-Out® Access Catheter System (Surfacer System)
E0231	Non-contact wound warming device (temperature control unit, ac adapter and power cord) for use with warming card and wound cover.	
E0232	Warming card for use with the non contact wound warming device and non contact wound warming wound cover	
G0069	Professional services for the administration of subcutaneous immunotherapy for each infusion drug administration calendar day in the individual's home, each 15 minutes	—
J1096	Dexamethasone, lacrimal ophthalmic insert, 0.1 mg	Dextenza® by Ocular Therapeutix, Inc.
J7401	Mometasone furoate sinus implant, 10 micrograms	—
J7402	Mometasone furoate sinus implant, (sinuva), 10 micrograms	SINUVA

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

K1004	Low frequency ultrasonic diathermy treatment device for home use, includes all components and accessories	—
K1007	Bilateral hip, knee, ankle, foot device, powered, includes pelvic component, single or double upright(s), knee joints any type, with or without ankle joints any type, includes all components and accessories, motors, microprocessors, sensors	ReWalk™ Exoskeleton by ReWalk Robotics
K1009	Speech volume modulation system, any type, including all components and accessories	SpeechVive by SpeechVive Inc.
K1030	External recharging system for battery (internal) for use with implanted cardiac contractility modulation generator, replacement only	Cardiac Contractility Modulation for Chronic Heart Failure (i.e., Optimizer by Impulse Dynamics)

CPT U Codes (Proprietary Laboratory Analyses codes)

Code	Description	Proprietary Name and Clinical Laboratory and/or Manufacturer
0002U	Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps	PolypDX™ by Atlantic Diagnostic Laboratories, LLC, and Metabolomic Technologies Inc.
0025U	Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative	UrSure by UrSure, Inc.
0054U	Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service	AssuranceRX Micro Serum Test by Firstox™
0058U	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative	Merkel SmT Oncoprotein Antibody Titer, University of Washington Department of Laboratory Medicine
0059U	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative	
0061U	Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis	Spatial Frequency Domain Imaging (SFDI) by Modulated Imaging, Inc.

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

0086U	Infectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility	Accelerate PhenoTest™ BC kit by Accelerate Diagnostics, Inc.
0087U	Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score	Molecular Microscope® MMDx—Heart test by Kashi Clinical Laboratories.
0088U	Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection	Molecular Microscope® MMDx—Kidney test by Kashi Clinical Laboratories
0089U	Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es)	Pigmented Lesion Assay (PLA) by DermTech
0090U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a categorical result (ie, benign, indeterminate, malignant)	myPath® Melanoma by Myriad
0095U	Inflammation (eosinophilic esophagitis), ELISA analysis of eotaxin-3 (CCL26 [C-C motif chemokine ligand 26]) and major basic protein (PRG2 [proteoglycan 2, pro eosinophil major basic protein]), specimen obtained by swallowed nylon string, algorithm reported as predictive probability index for active eosinophilic esophagitis	Esophageal String Test™ (EST) by Cambridge Biomedical, Inc.
0096U	Human papillomavirus (HPV), high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), male urine	HPV, High-Risk, Male Urine by Molecular Testing Labs
0105U	Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD)	KidneyIntelXTM, RenalytixAI
0107U	Clostridium difficile toxin(s) antigen detection by immunoassay technique, stool, qualitative, multiple-step method	Singulex Clarity C.diff toxins A/B assay by Singulex
0108U	Gastroenterology (Barrett’s esophagus), whole slide–digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16,	TissueCypher® Barrett’s Esophagus Assay by Cernostics

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

	AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer	
0109U	Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species (A. fumigatus, A. terreus, A. niger, and A. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species	MYCODART Dual Amplification Real Time PCR Panel for 4 Aspergillus species, RealTime Laboratories, Inc/MycoDART, Inc
0110U	Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected	Oral OncolyticAssuranceR X, Firsttox Laboratories, LLC
0112U	Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene	MicroGenDX qPCR & NGS for Infection, MicroGenDX
0114U	Gastroenterology (Barrett’s esophagus), VIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett’s esophagus	EsoGuard™ by Lucid Diagnostics
0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected	ePlex Respiratory Pathogen (RP) Panel, GenMark Diagnostics, Inc
0116U	Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with LC-MS/MS, oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug to drug interactions for prescribed medications	Snapshot Oral Fluid Compliance, Ethos Laboratories
0117U	Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA), quinolinic acid, kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain	Foundation PI SM by Ethos Laboratories
0118U	Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA	Viracor TRACTM dd-cfDNA, Viracor Eurofins

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

0121U	Fetal congenital abnormalities, biochemical assays of 3 analytes (free beta-hCG, PAPP-A, AFP), time-resolved fluorescence immunoassay, maternal dried-blood spot, algorithm reported as risk scores for fetal trisomies 13/18 and 21	Flow Adhesion of Whole Blood on VCAM-1 (FAB-V) by Functional Fluidics
0122U	Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood	Flow Adhesion of Whole Blood to P-SELECTIN (WB-PSEL), by Functional Fluidics
0123U	Mechanical fragility, RBC, shear stress and spectral analysis profiling	Mechanical Fragility, RBC by shear stress profiling and spectral analysis by Functional Fluidics
0125U	Fetal congenital abnormalities and perinatal complications, biochemical assays of 5 analytes (free beta-hCG, PAPP-A, AFP, placental growth factor, and inhibin-A), time-resolved fluorescence immunoassay, maternal serum, algorithm reported as risk scores for fetal trisomies 13/18, 21, and preeclampsia	Maternal Fetal Screen T1SM, Eurofins NTD, LLC
0126U	Fetal congenital abnormalities and perinatal complications, biochemical assays of 5 analytes (free beta-hCG, PAPP-A, AFP, placental growth factor, and inhibin-A), time-resolved fluorescence immunoassay, includes qualitative assessment of Y chromosome in cell-free fetal DNA, maternal serum and plasma, predictive algorithm reported as a risk scores for fetal trisomies 13/18, 21, and preeclampsia	Maternal Fetal Screen T1 + Y Chromosome SM, Eurofins NTD, LLC
0127U	Obstetrics (preeclampsia), biochemical assays of 3 analytes (PAPP-A, AFP, and placental growth factor), time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia	Preeclampsia Screen T1SM, Eurofins NTD, LLC
0128U	Obstetrics (preeclampsia), biochemical assays of 3 analytes (PAPP-A, AFP, and placental growth factor), time-resolved fluorescence immunoassay, includes qualitative assessment of Y chromosome in cell-free fetal DNA, maternal serum and plasma, predictive algorithm reported as a risk score for preeclampsia	Preeclampsia Screen T1 + Y Chromosome SM, Eurofins NTD, LLC
0136U	ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure)	+RTMinsight™ for ATM by Ambry Genetics
0139U	TERMED 10/1/2021 Neurology (autism spectrum disorder [ASD]), quantitative measurements of 6 central carbon metabolites (ie, α-ketoglutarate, alanine, lactate, phenylalanine, pyruvate, and	NeuroPointDX-NPDX ASD by NeuroPoint Dx

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

	succinate), LC-MS/MS, plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)	
0140U	Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected	
0141U	Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected	
0142U	Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected	
0151U	TERMED 3/31/2022 Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 33 targets, real-time semi-quantitative PCR, bronchoalveolar lavage, sputum, or endotracheal aspirate, detection of 33 organismal and antibiotic resistance genes with limited semi-quantitative results	BioFire® FilmArray® Pneumonia Panel by Biomérieux
0152U	Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA, PCR and next-generation sequencing, plasma, detection of >1,000 potential microbial organisms for significant positive pathogens	Karius® Test by Karius
0156U	Copy number (eg, intellectual disability, dysmorphology), sequence analysis	SMASH™ Genomic Assay by Marvel Genomics®
0164U	Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-CdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results	IBSchek®, Commonwealth Diagnostics International, Inc
0166U	Liver disease, 10 biochemical assays (α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation	LiverFASt™, Fibronostics
0167U	Gonadotropin, chorionic (hCG), immunoassay with direct optical observation, blood	ADEXUSDx hCG Test, NOWDiagnostics

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
----------------	---

0170U	Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis	Clarifi™, Quadrant Biosciences, Inc
0174U	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents	LC-MS/MS Targeted Proteomic Assay, OncoOmicDx Laboratory, LDT
0176U	Cytotoxic distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA)	IBSChek®, Commonwealth Diagnostics International, Inc
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	BioFire Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2
0203U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	QIAstat-Dx Respiratory SARS-CoV-2 Panel
0206U	Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCε) concentration in response to amyloid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease	DISCERN, NeuroDiagnostics,
0207U	Disease quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure)	DISCERN, NeuroDiagnostics,
0210U	Syphilis test, non-treponemal antibody, immunoassay, quantitative (RPR)	BioPlex 2200 RPR Assay - Quantitative, Bio-Rad Laboratories
0219U	Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility	Sentosa® SQ HIV-1 Genotyping Assay, Vela Diagnostics USA,
0220U	Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score	PreciseDx™ Breast Cancer Test, PreciseDx, PreciseDx

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

0228U	Oncology (prostate), multianalyte molecular profile by photometric detection of macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first morning voided urine, algorithm reported as likelihood of prostate cancer	PanGIA Prostate, Genetics Institute of America, Entopsis, LLC
0243U	Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia	PIGF Preeclampsia Screen, PerkinElmer
0247U	Obstetrics (preterm birth), insulin-like growth factor-binding protein 4 (IBP4), sex hormone-binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth	PreTRM®, Sera Prognostics, Sera Prognostics, Inc®
0251U	Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma	Intrinsic Hepcidin IDx™ Test, IntrinsicDx, Intrinsic LifeSciences™
0255U	Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score	Cap-Score™ Test, Androvia LifeSciences Lab
0259U	Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myo-inositol, valine, and creatinine, algorithmically combined with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative	GFR by NMR, Labtech™ Diagnostics
0261U	Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score	Immunoscore®, HalioDx, HalioDx
0262U	Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed paraffinembedded (FFPE), algorithm reported as gene pathway activity score	OncoSignal 7 Pathway Signal, Protean BioDiagnostics, Philips Electronics Nederland BV
0263U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 16 central carbon metabolites (ie, ?ketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, S-sulfocysteine, taurine, urate, and xanthine), liquid	NPDX ASD and Central Carbon Energy Metabolism, Stemina Biomarker Discovery, Inc.

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

	chromatography tandem mass spectrometry (LC-MS/MS), plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)	
0311U	Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)–based antimicrobial susceptibility for each organism identified	Accelerate PhenoTest® BC kit, AST configuration, Accelerate Diagnostics, Inc.
0312U	Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment	Awise® Lupus, Exagen Inc.
0316U	Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine	
0344U	Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASH	OWLiver®, CIMA Sciences, LLC
0346U	Beta amyloid, Aβ40 and Aβ42 by liquid chromatography with tandem mass spectrometry (LC-MS/MS), ratio, plasma	QUEST AD-Detect™, Beta-Amyloid 42/40 Ratio, Plasma Quest Diagnostics
0351U	Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP10), and C-reactive protein, serum, algorithm reported as likelihood of bacterial infection	MeMed BV®, MeMed Diagnostics, Ltd
0352U	Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of bacterial vaginosis–associated bacteria (BVAB-2, Atopobium vaginae, and Megasphera type 1), algorithm reported as detected or not detected and separate detection of Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, and trichomonas vaginalis, vaginal-fluid specimen, each result reported as detected or not detected	Xpert® Xpress MVP, Cepheid®
0322U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass	NPDX ASD Test Panel III, NeuroPointDX

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

	spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD	
0357U	Oncology (melanoma), artificial intelligence (AI)-enabled quantitative mass spectrometry analysis of 142 unique pairs of glycopeptide and product fragments, plasma, prognostic, and predictive algorithm reported as likely, unlikely, or uncertain benefit from immunotherapy agents	DAWN™ IO Melanoma, InterVenn Biosciences, California
0358U	Neurology (mild cognitive impairment), analysis of β-amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative	Lumipulse® G β-Amyloid Ratio (1-42/1-40) Test, Fujirebio Diagnostics, Inc., Pennsylvania
0361U	Neurofilament light chain, digital immunoassay, plasma, quantitative	Neurofilament Light Chain (NfL), Mayo Clinic

REVIEW OF EVIDENCE

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding each of the medical technologies listed below in the CPT/HCPCS CODE section above. The evidence was insufficient to support the clinical utility, diagnostic efficacy, and/or safety of these technologies. Evidence reviews and summaries for each technology addressed in this policy may be made available upon request.

INSTRUCTIONS FOR USE

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days’ notice of policy changes that are restrictive in nature.

The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

MEDICAL POLICY	Investigational and Non-Covered Medical Technologies (All Lines of Business Except Medicare)
-----------------------	---

REGULATORY STATUS

Mental Health Parity Statement

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.